SHJBF (Shanghai Junshi Biosciences Co) Growth Rank: 9 (As of Sep. 12, 2026) — 29% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHJBF Shanghai Junshi Biosciences Co Ltd SHJBF
68 GF Score
Price $3.35
GF Value $6.72
! 4 Warning Signs
View Full Analysis

What is Shanghai Junshi Biosciences Co Growth Rank?

Shanghai Junshi Biosciences Co SHJBF +11.67% 68 Growth Rank is 9 as of Sep. 12, 2026, which is 29% above its 10-year median of 7.00. GuruFocus rates SHJBF with a GF Score™ of 68/100 and a GF Value™ of $6.72. The stock has 4 warning signs investors should review.

Shanghai Junshi Biosciences Co has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Shanghai Junshi Biosciences Co Growth Rank Related Terms

SHJBF vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Growth Rank falls into.


SHJBF
68GF Score
Shanghai Junshi Biosciences Co Ltd SHJBF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
Shanghai Junshi Biosciences Co (SHJBF) has a Growth Rank of 9 as of Sep. 12, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Shanghai Junshi Biosciences Co and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, Shanghai Junshi Biosciences Co's Growth Rank has ranged from 4.00 to 9.00.
Is Shanghai Junshi Biosciences Co's Growth Rank too high?
Shanghai Junshi Biosciences Co's current Growth Rank of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Growth Rank compare to VRTX and REGN?
Shanghai Junshi Biosciences Co's Growth Rank of 9 can be compared against companies in the Biotechnology industry. Historically, Shanghai Junshi Biosciences Co's own Growth Rank has ranged from 4.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Shanghai Junshi Biosciences Co and its competitors. Shanghai Junshi Biosciences Co's current Growth Rank is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Shanghai Junshi Biosciences Co (SHJBF) has a current Growth Rank of 9. The stock's GF Value™ is $6.72, compared to a current price of $3.35 — trading 50.1% below its estimated fair value. The current Growth Rank is 9, which is 29% above median its 10-year median of 7.00. Shanghai Junshi Biosciences Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current Growth Rank is 9 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued. The current stock price of $3.35 is trading 50.1% below its estimated GF Value™ of $6.72.

Key valuation signals for SHJBF:

  • Growth Rank: 9 (29% above median its 10-year median of 7.00)
  • GF Value™: $6.72 vs. price of $3.35 (50.1% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Junshi Biosciences Co Business Description

Other Exchanges 01877:Hong Kong688180:China
Address No. 987 Cai Lun Road, Level 4, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
68GF Score

Get the complete analysis for SHJBF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$6.72
GF Value